Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 114Leukemia, Myeloid, Acute 103Leukemia 83Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Myeloproliferative Disorders 65Leukemia, Myelogenous, Chronic, BCR-ABL Positive 61Leukemia, Myelomonocytic, Chronic 60Lymphoma, Non-Hodgkin 56Leukemia, Lymphocytic, Chronic, B-Cell 53Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 41Blast Crisis 41Leukemia, Myeloid, Chronic-Phase 40Multiple Myeloma 39Hodgkin Disease 37Lymphoma 35Leukemia, Myeloid, Accelerated Phase 35Congenital Abnormalities 35Anemia, Refractory, with Excess of Blasts 35Primary Myelofibrosis 33Lymphoma, Follicular 33Lymphoma, Large B-Cell, Diffuse 32Burkitt Lymphoma 30Lymphoma, Mantle-Cell 29Myelodysplastic-Myeloproliferative Diseases 27Lymphoma, Large-Cell, Immunoblastic 27Lymphoma, B-Cell, Marginal Zone 27Polycythemia Vera 24Thrombocythemia, Essential 23Neuroblastoma 23Neoplasms, Plasma Cell 23

Interventions

ruxolitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hypereosinophilic Syndrome × Myeloid × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡